학술논문

Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
Document Type
Article
Source
In The Lancet 7-13 January 2023 401(10370):38-48
Subject
Primary Research
Articles
Language
ISSN
0140-6736